The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 696 currently available and novel biosimilar products, detailing…
Diabetic macular edema (DME) is a complication of diabetic retinopathy (DR) derived from chronically high blood sugar levels, resulting in vision loss and blindness, if left untreated. DME…
Retinal vein occlusion (RVO) is a major cause of blindness in the major pharmaceutical markets. Patients are segmented by the anatomic location of the occlusion; thus, they are classified as having…
Bipolar disorder (BPD) is a spectrum disorder encompassing two main symptom domains: mania and depression. Atypical antipsychotics, lithium, antiepileptic drugs (AEDs), and antidepressants are the…
In 2021, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $130 billion in the major pharmaceutical markets under study (United…
In 2021, sales of branded biologics in immunology exceeded $70 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…
In 2021, sales of branded biologics for oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology indications exceeded $130 billion in the major pharmaceutical markets under…
In 2021, sales of branded MAb biologics in oncology exceeded $36 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5…
The gastroesophageal cancer therapy market (including gastric, gastroesophageal junction, and esophageal cancer) is rapidly evolving and experiencing substantial growth, largely driven by the…
In 2021, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $2.5 billion in the major pharmaceutical markets under study (…
In 2021, sales of insulins at the ex-manufacturer price level exceeded $20 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031 forecast…
Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…
In 2021, sales of branded biologics for respiratory indications totaled about $0.7 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2021-2031…
In 2021, sales of branded biologics in ophthalmology totaled more than $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2021-2031 forecast period, the…
With an increasing prevalence owing to aging populations, the major-market osteoporosis patient pool is large and growing. The combined influence of increased patient numbers, increasing uptake of…